Redhill Biopharma Ltd (RDHL)

Redhill Biopharma Ltd (RDHL) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $3M; returns 1 day +0.3%, 1 week -11.9%, 1 year -75.5%.

Redhill Biopharma Ltd. is a specialty biopharmaceutical company with a primary focus on gastrointestinal and infectious diseases. The company's main revenue driver is the commercial sale of Talicia®, an FDA-approved oral capsule for the treatment of Helicobacter pylori (H. pylori) infection in adults. Historically, it also generated revenue from Aemcolo® for travelers' diarrhea.

Groups RDHL belongs to

• Pharmaceuticals
• Israel Companies
• Biopharmaceutical
• Gastroenterology
• Infectious Diseases
• Commercial Stage
• Specialty Chemicals
• Oncology
• Healthcare

RDHL financial model: income statement, cash flow and balance sheet